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ReportsMicroRNA Profiling in Benign
and Malignant Conjunctival
Melanocytic LesionsConjunctival melanoma is a rare tumor with an incidence of 0.2 to
0.8 cases per 1 million people, although the incidence is increasing.
Local recurrences and metastases are common.1 Up to 17% of the
melanoma arise from nevi.2 In contrast to skin melanoma, for
which many risk factors for a malignant course are known, the
risk factors for conjunctival melanoma are currently not well
understood, despite many attempts to predict the lesions’
behavior by clinical and histopathologic characteristics and
molecular parameters.1e3 A stringent follow-up and aggressive
management is required to prevent significant morbidity and
mortality, with only limited treatment options after a lesion has
metastasized.2 These factors emphasize the need for informative
biomarkers that can predict the lesion’s behavior at an early
stage of the disease.
During the last decades, microRNAs (miRNAs) have gath-
ered interest with regard to their role in physiologic processes
and can act either like a tumor suppressor or an oncogene.4
Because of the similarities between skin melanoma and
conjunctival melanoma2 and the promising results of the
involvement of miRNAs in skin melanoma,5 miRNAs may
play an important role in the development of conjunctival
melanoma as well.
In this study, we focused on discriminating miRNA levels in
benign versus malignant conjunctival melanocytic lesions and
differences in miRNA levels in the conjunctival melanoma with
versus without metastases to determine whether it is possible to
predict metastatic potential. For the first analysis, we used a
discovery set consisting of 6 nevi and 20 melanoma cases,
collected at the Department of Pathology, Erasmus MC-
University Medical Center, Rotterdam, the Netherlands. For
validation of the results, an independent validation cohort,
consisting of 19 melanoma and 13 nevi cases from the Uni-
versity Hospital Leuven, Leuven, Belgium, was used. The non-
metastatic cases in the discovery set had a median follow-up of
7 years (range, 4.8e14.3 years for nevi and 0.1e21.4 years for
conjunctival melanoma without metastases) and a median
follow-up of 4 years (range, 0.6 to 6.9 years) for melanoma with
metastasis. The patients from the University Hospital Leuven
had a median follow-up for melanoma of 7 years (range,
0.0e15.0 years) and for nevi of 0.3 years (range, 0.0e10.6
years); Table S1, available at www.aaojournal.org. Ethics
committee approval was obtained. All research adhered to the
tenets of the Declaration of Helsinki. Due to the
noninterventional retrospective nature of the study informed
consent was not required.
The relevant slides were reviewed and subsequently, tumor-
rich tissue was selected, containing at least 60% tumor cells,
avoiding contamination with normal epithelium or inflammatoryinfiltrate. The formalin-fixed paraffin-embedded tissue, as is
suitable for this analysis method,6 was cut, and the
macrodissected tumor was dissolved in Trizol Reagent
(ThermoFisher Scientific, PN 15596018; Bleiswijk, the
Netherlands). Subsequently, total RNA was isolated using the
Direct-zol RNA microPrep Kit from Zymo Research (Base-
clear, art. no. R2062; Leiden, The Netherlands). After different
quality checks, RNA samples of suitable quality (quantification
cycle [Cq] value <32 for RNU48) were subjected to miRNA
profiling using the TaqMan Low Density Array Card A
(ThermoFisher Scientific) as described in the manufacturer’s
protocol.
The TaqMan miRNA array output data were uploaded in the
ThermoFisher Cloud App and were analyzed using defined
threshold settings for each individual miRNA. Because of the
variability of the quality of the formalin-fixed paraffin-
embedded tissue samples, different normalization procedures
were applied. After normalization, the data were analyzed using
the statistical tools in QbasePlus (Zwijnaarde, Belgium) (Manne
Whitney U test with correction for multiple testing). Amplification
curves of potential targets were inspected in the ThermoFisher
Cloud App and those exhibiting robust amplification were selected
for further investigation using individual TaqMan assays. SPSS
statistics software version 24 (SPSS, Inc; IBM-Netherlands,
Amsterdam, The Netherlands) was used for constructing the
receiver operating characteristic (ROC) curves and to calculate the
area under the ROC curve.
We analyzed conjunctival nevi versus primary conjunctival
melanoma with versus without metastasis. In the discovery cohort,
miR-9-5p, miR-18b-5p, miR-196-5p, miR-425-5p, miR-450a-5p,
miR-501-5p, and miR-615-3p showed significant differential levels,
with a higher median Cq-value concerning the raw data for the
melanoma group compared with the nevi group (Fig S1A
[normalized data], Table S2 [raw data and normalized data],
available at www.aaojournal.org). The miRNAs in the independent
cohort as well as evaluating all samples combined revealed a
similar pattern, with at least a P value  0.001 for miR-9-5p, miR-
196b-5p, miR-450a-5p, miR-501-5p, and miR-615-3p. Combining
the 3 best performing miRNAs (miR-196b-5p, miR-615-3p, and
miR-9-5p) resulted in an area under the ROC curve of 1.00 for the
discovery cohort and of 0.98 for the independent validation cohort
(0.983 and 0.972 for the combination of miR-615-3p and miR-9-5p,
respectively; Table 1). No differences in miRNA levels were found
in the melanoma group with versus without metastasis (Fig S1B,
Table S2; available at www.aaojournal.org).
Discussion
In this study, we focused on upregulated miRNAs, because this
finding is less influenced by factors like the amount and quality
of the available tissue. This makes detecting upregulated miR-
NAs attractive for implementation in routine diagnostics. In1
Table 1. MicroRNAs for Discrimination of Benign and Primary Malignant Melanocytic Lesions
Discovery Cohort Validation Cohort
Nevi Melanoma Nevi Melanoma
6 20 13 19









Area under the ROC Curve
Combined microRNAs
miR-196b-5p, miR-615-3p, and miR-9-5p 1.000 0.980
miR-615-3p and miR-9-5p 0.983 0.972
Individual TaqMan assays were carried out for samples from formalin-fixed paraffin-embedded tissues from the Erasmus University Medical Center (discovery
cohort) and the University Hospital Leuven (validation cohort). Fold change for the melanoma and nevi cohorts and ManneWhitney U test results with
correction formultiple testingP values are fromQbasePlus and the areas under the receiver operating characteristic (ROC) curve are fromSPSS softwareversion24.
Ophthalmology Volume -, Number -, Month 2019daily practice, it can be very difficult to distinguish a benign
from a malignant melanocytic lesion based on only histologic,
immunohistochemical, and the well-known molecular findings.3
However, predicting the behavior of the melanocytic lesion is of
high clinical importance. In this study, 5 miRNAs (of 377
miRNAs [1.3%]) show increased levels in conjunctival
melanoma compared with nevi, with combined higher levels
of miR-9-5p, miR-196b-5p and miR-615-3p strongly associ-
ated with malignancy. This combination of miRNAs is certainly
of interest with regard to the pathogenesis of conjunctival
melanoma, in which a shared pathway for these miRNAs is
suggested, possibly involving the homeobox gene clusters.7
Furthermore, this combination may be of additional use in
routine diagnostics to discriminate benign from malignant
conjunctival melanocytic lesions, in case the amount of tissue
or the currently available techniques seem to be insufficient.
Additionally, miRNAs may be of interest with regard to
targeted therapy. Unfortunately, we did not find miRNAs that
could predict metastatic potential, emphasizing the need for
further studies on this subject. MicroRNA profiling also will
be of interest in the evaluation of primary acquired melanosis,
because this condition is considered a risk factor for the
development of melanoma1 and grading of primary acquired
melanosis using a more objective method would have major
consequences for both therapy and follow-up. However, to
obtain reliable results, it is very important to avoid contamina-
tion of the atypical melanocytes with adjacent tissue. To over-
come this problem, laser microdissection of single atypical
melanocytes could be used in a research setting. However, such
a laborious method would be less attractive for implementation
in routine diagnostics. In the future, the diagnosis possibly may
be made based on liquid biopsies in blood or tear film, rendering
the histopathologic features no longer applicable.2
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